Drug and Alcohol Services, South East Sydney Local Health District, Sydney, NSW, Australia.
Department of Addiction Medicine, Faculty Medicine and Health, University of Sydney, 591 South Dowling Street, Surry Hills, NSW, 2010, Australia.
Harm Reduct J. 2022 Jul 30;19(1):88. doi: 10.1186/s12954-022-00666-w.
Australia has had a framework for legal medicinal cannabis since 2016, yet prior online surveys in 2016 and 2018 indicated that most consumers continued to use illicit medical cannabis products. Regulatory data indicate an increase in the prescription of medicinal cannabis since 2019, and this survey examines consumer experiences of prescribed and illicit medical cannabis (MC) use in Australia.
A cross-sectional anonymous online survey was administered September 2020 to January 2021. Recruitment via social media, professional and consumer forums, and medical practices. Participant eligibility: ≥ 18 years; used a cannabis product for self-identified medical reason(s) in the past year, and resident in Australia. Outcome measures included consumer characteristics, conditions treated, source and patterns of MC use, and perspectives on accessing MC.
Of the 1600 participants (mean age 46.4 ± 14.3 years, 53% male), 62.4% (n = 999) reported using only illicit and 37.6% (n = 601) used prescribed MC in the past year. MC was used on a median of 28 (IQR: 12, 28) of the past 28 days and cost $AUD 74 ± 72 weekly (median = $40, IQR: $7, $100). Prescribed participants were more likely to treat pain conditions than those using illicit MC (52% v 40%, OR = 1.7, 1.3-2.1) and less likely to treat sleep conditions (6% v 11%, OR = 0.5, 0.3-0.8), with mental health conditions also a common indication in both groups (26%, 31%). Prescribed MC was consumed predominately by oral routes (72%), whereas illicit MC was most commonly smoked (41%). Prescribed MC was 'mainly THC' (26%), 'equal THC/CBD' (40%), 'mainly CBD' (31%) and 'uncertain' (3%), while 34% of those using illicit MC were 'uncertain' of the cannabinoid profile. Cost and difficulties finding medical practitioners to prescribe remain significant barriers to accessing prescribed MC, and few (10.8%) described the existing model for accessing prescribed MC as 'straightforward or easy'.
There has been a notable shift from illicit to prescribed MC by many consumers compared to prior surveys. Consumers using prescribed MC reported a range of advantages compared to illicit MC, including safer routes of administration, and greater certainty regarding access and composition of products.
自 2016 年以来,澳大利亚已经有了一个合法医用大麻的框架,但 2016 年和 2018 年的先前在线调查表明,大多数消费者仍在继续使用非法医用大麻产品。监管数据显示,自 2019 年以来,医用大麻的处方数量有所增加,本调查研究了澳大利亚规定的和非法医用大麻(MC)使用的消费者体验。
2020 年 9 月至 2021 年 1 月进行了一项横断面匿名在线调查。通过社交媒体、专业和消费者论坛以及医疗实践进行招募。参与者资格:≥18 岁;在过去一年中,因自我认定的医疗原因使用过大麻产品,且居住在澳大利亚。主要结果衡量标准包括消费者特征、治疗的病症、MC 使用的来源和模式,以及获取 MC 的看法。
在 1600 名参与者中(平均年龄 46.4±14.3 岁,53%为男性),62.4%(n=999)报告仅使用非法大麻,37.6%(n=601)在过去一年中使用规定的 MC。MC 在过去 28 天的中位数使用天数为 28 天(IQR:12,28),每周费用为 74 澳元(中位数为 40 澳元,IQR:7 澳元,100 澳元)。规定的 MC 使用者更有可能治疗疼痛病症,而不是使用非法 MC 的人(52%比 40%,OR=1.7,1.3-2.1),不太可能治疗睡眠病症(6%比 11%,OR=0.5,0.3-0.8),心理健康病症也是两组常见的病症(26%,31%)。规定的 MC 主要通过口服途径(72%)消耗,而非法 MC 最常通过吸烟(41%)。规定的 MC 主要为“主要含 THC”(26%)、“THC/CBD 含量相等”(40%)、“主要含 CBD”(31%)和“不确定”(3%),而使用非法 MC 的 34%的人对大麻素成分“不确定”。费用和难以找到医生开处方仍然是获得规定 MC 的重大障碍,很少有(10.8%)人认为现有的获得规定 MC 的模式“简单或容易”。
与之前的调查相比,许多消费者已经从非法 MC 转向了规定的 MC。与非法 MC 相比,使用规定的 MC 的消费者报告了一系列优势,包括更安全的给药途径,以及对产品的获取和成分的更大确定性。